Home DNA Damage/DNA Repair PARP inhibitor Rucaparib phosphate For research use only.

Rucaparib phosphate

Synonyms: AG-014699 phosphate, PF-01367338 phosphate

Rucaparib phosphate is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Rucaparib phosphate Chemical Structure

Rucaparib phosphate Chemical Structure

CAS: 459868-92-9

Selleck's Rucaparib phosphate has been cited by 127 publications

Purity & Quality Control

Batch: Purity: 99.89%
99.89

Other PARP Products

Related compound libraries

Choose Selective PARP Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 Function Assay 0.1/1/500/1000 nM inhibits PARP activity at starting concerntration of 500 nM 25128455
BT474 Growth Inhibition Assay 500 nM 10–15 d reduces cell growth in the four lines and significantly 25128455
SKBR3 Growth Inhibition Assay 500 nM 10–15 d reduces cell growth in the four lines and significantly 25128455
AU565 Growth Inhibition Assay 500 nM 10–15 d reduces cell growth in the four lines and significantly 25128455
EFM192A Growth Inhibition Assay 500 nM 10–15 d reduces cell growth in the four lines and significantly 25128455
MDA-MB-231 Function Assay 10/20/40 μM 24 h increases p-AKT levels in a dose-dependent manner 24420152
MDA-MB-231 Cell Viability Assay 0.1-40 μM 24 h IC50 = 17.77 μM 24420152
MDA-MB-231 Apoptosis Assay 10/20/40 μM 24 h induces apoptosis dose dependently 24420152
MDA-MB-231 Growth Inhibition Assay 10/20/40 μM 24 h blocks cell cycle progression in G2/M phase 24420152
H460 Growth Inhibition Assay 400 nM 24 h increases cellular radiosensitivity 24411611
A549  Growth Inhibition Assay 400 nM 24 h increases cellular radiosensitivity 24411611
DT40 Growth Inhibition Assay IC50=21 nM 24356813
DU145 Growth Inhibition Assay IC50=18 nM 24356813
COLO704 Growth Inhibition Assay IC50=2.52 ± 0.67 μM 23729402
OVMANAb Growth Inhibition Assay IC50=2.58 ± 0.38 μM 23729402
OV177 Growth Inhibition Assay IC50=2.78 ± 0.71 μM 23729402
OAW28 Growth Inhibition Assay IC50=3.61 ± 0.28 μM 23729402
OVSAHO Growth Inhibition Assay IC50=3.64 ± 0.33 μM 23729402
OVKATE Growth Inhibition Assay IC50=3.64 ± 1.79 μM 23729402
OVCAR3 Growth Inhibition Assay IC50=3.74 ± 0.40 μM 23729402
PEO14 Growth Inhibition Assay IC50=3.84 ± 0.76 μM 23729402
A2780 Growth Inhibition Assay IC50=3.94 ± 0.25 μM 23729402
OVTOKO Growth Inhibition Assay IC50=4.14 ± 1.53 μM 23729402
KURAMOCHIb Growth Inhibition Assay IC50=4.34 ± 0.29 μM 23729402
TOV21G Growth Inhibition Assay IC50=5.07 ± 1.30 μM 23729402
OVISE Growth Inhibition Assay IC50=5.68 ± 0.23 μM 23729402
KK Growth Inhibition Assay IC50=6.15 ± 1.42 μM 23729402
RMUGS Growth Inhibition Assay IC50=7.03 ± 1.83 μM 23729402
PEO6 Growth Inhibition Assay IC50=7.06 ± 0.74 μM 23729402
OVCA429 Growth Inhibition Assay IC50=8.29 ± 1.64 μM 23729402
OV167 Growth Inhibition Assay IC50=8.33 ± 1.18 μM 23729402
RMG1 Growth Inhibition Assay IC50=9.32 ± 2.36 μM 23729402
OVCAR5 Growth Inhibition Assay IC50=9.50 ± 2.59 μM 23729402
EFO21 Growth Inhibition Assay IC50=9.92 ± 1.87 μM 23729402
ES2 Growth Inhibition Assay IC50=10.12 ± 1.23 μM 23729402
Tyk-nu Growth Inhibition Assay IC50=10.20 ± 1.12 μM 23729402
CAOV3 Growth Inhibition Assay IC50=10.37 ± 0.87 μM 23729402
OV207 Growth Inhibition Assay IC50=12.27 ± 0.32 μM 23729402
HEY Growth Inhibition Assay IC50=13.01 ± 0.75 μM 23729402
DOV13 Growth Inhibition Assay IC50>15 μM 23729402
EFO27 Growth Inhibition Assay IC50>15 μM 23729402
HEY C2 Growth Inhibition Assay IC50>15 μM 23729402
KOC-7cc Growth Inhibition Assay IC50>15 μM 23729402
MCASb Growth Inhibition Assay IC50>15 μM 23729402
OAW42 Growth Inhibition Assay IC50>15 μM 23729402
OV2008 Growth Inhibition Assay IC50>15 μM 23729402
OV90 Growth Inhibition Assay IC50>15 μM 23729402
OVCA420b Growth Inhibition Assay IC50>15 μM 23729402
OVCA432 Growth Inhibition Assay IC50>15 μM 23729402
PEA2 Growth Inhibition Assay IC50>15 μM 23729402
SKOV3 Growth Inhibition Assay IC50>15 μM 23729402
TOV112D Growth Inhibition Assay 0-3 μM IC50>15 μM 23729402
C4-2 Growth Inhibition Assay 0-3 μM 14 d DMSO decreases colony number dose dependently 23565244
PC3 Growth Inhibition Assay 0-3 μM 14 d DMSO decreases colony number dose dependently 23565244
DU145 Growth Inhibition Assay 0-3 μM 14 d DMSO decreases colony number dose dependently 23565244
VCaP  Growth Inhibition Assay 0-3 μM 14 d DMSO decreases colony number dose dependently 23565244
LNCaP  Growth Inhibition Assay 0-3 μM 14 d DMSO decreases colony number dose dependently 23565244
MDA-MB-468 Cell Viability Assay IC50=9.7 μM 22678161
MDA-MB-231 Cell Viability Assay IC50=13 μM 22678161
Cal-51 Cell Viability Assay IC50=8.6 μM 22678161
LoVo Function assay 30 mins Inhibition of PARP in human LoVo cells assessed as inhibition of poly(ADP)-ribose polymerization for 30 mins by fluorescence assay, EC50 = 0.00469 μM. 26652717
MX1 Cytotoxicity assay Cytotoxicity against BRCA1-deficient human MX1 cells, EC50 = 0.0053 μM. 26652717
Rosetta2 (DE3) Function assay Inhibition of human N-terminal 6xhis-tagged ARTD6 (873 to 1161) expressed in Escherichia coli Rosetta2 (DE3) cells using NAD+ as substrate by fluorescence assay, IC50 = 0.014 μM. 24900770
Rosetta2 (DE3) Function assay Inhibition of human 6xhis-tagged ARTD5 (1030 to 1317) expressed in Escherichia coli Rosetta2 (DE3) cells using NAD+ as substrate by fluorescence assay, IC50 = 0.025 μM. 24900770
LoVo Cytotoxicity assay 0.4 uM 5 days Potentiation of temozolomide-induced cytotoxicity in human LoVo cells assessed as temozolomide GI50 at 0.4 uM after 5 days by Celltiter-Glo assay, GI50 = 0.144 μM. 26652717
Capan1 Cytotoxicity assay Cytotoxicity against BRCA2-deficient human Capan1 cells, EC50 = 0.609 μM. 26652717
MDA-MB-436 Anticancer assay 96 hrs Anticancer activity against human BRCA1-deficient MDA-MB-436 cells after 96 hrs by MTT assay, CC50 = 3 μM. 26342868
OVCAR3 Antiproliferative assay 24 hrs Antiproliferative activity against human OVCAR3 cells after 24 hrs by MTT assay, IC50 = 3.31 μM. 29456106
MRC5 Cytotoxicity assay Cytotoxicity against human MRC5 cells, EC50 = 8.53 μM. 26652717
MCF7 Anticancer assay 96 hrs Anticancer activity against human MCF7 cells after 96 hrs by MTT assay, CC50 = 19.47 μM. 26342868
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells 29435139
Click to View More Cell Line Experimental Data

Biological Activity

Description Rucaparib phosphate is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.
Features The first PARP inhibitor used in clinical trials combined with temozolomide.
Targets
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
In vitro
In vitro Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells. Besides, Rucaparib binds detectably to eight other PARP domains, including PARP2, 3, 4, 10, 15, 16, TNKS1 and TNKS2. [1] [2] The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib could target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions. [3] Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells. [4]
Kinase Assay Ki Determination
Inhibition of human full-length recombinant PARP-1 by [32P]NAD+ incorporation is measured. The [32P]ADP-ribose incorporated into acid insoluble material is quantified using a PhosphorImager. Ki is calculated by nonlinear regression analysis.
Cell Research Cell lines D425Med, D283Med and D384Med cells
Concentrations 0.4 μM
Incubation Time 3 or 5 days
Method Medulloblastoma cell lines are seeded in 96-well plates at a density of 1 × 103, 3 × 103 and 3 × 103, respectively. At 24 hours (D384Med) or 48 hours (D283Med and D425Med) after seeding, the cells are exposed to various concentrations of temozolomide in the presence or absence of 0.4 μM Rucaparib. After 3 days (D425Med and D384Med) or 5 days (D283Med) of culture, cell viability is evaluated by a XTT cell proliferation kit assay. Cell growth is expressed as a percentage in relation to DMSO or 0.4 μM Rucaparib-alone controls. The concentration of temozolomide, alone or in combination with Rucaparib that inhibited growth by 50% (GI50) is calculated. The potentiation factor 50 (PF50) is defined as the ratio of the GI50 of temozolomide in the presence of Rucaparib to the GI50 of temozolomide alone.
Experimental Result Images Methods Biomarkers Images PMID
Western blot PAR BRCA1 27960087
Growth inhibition assay Cell viability 31119062
Immunofluorescence α-tubulin PAR γH2AX 53BP1 30589644
In Vivo
In vivo Rucaparib is not toxic but significantly enhances temozolomide-induced TGD in the DNA repair protein-competent D384Med xenografts. Pharmacokinetics studies also show that Rucaparib is detected in the brain tissue, which indicates that Rucaparib has potential in intra-cranial malignancy therapy. [4] Rucaparib significantly potentiates the cytotoxicity of topotecan and temozolomide in NB-1691, SH-SY-5Y, and SKNBE (2c) cells. Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts. [5]
Animal Research Animal Models CD-1 nude mice bearing established D283Med xenografts
Dosages 1 mg/kg
Administration One or four daily by i.p.
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04539327 Completed Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Cancer Grupo Español de Investigación en Cáncer de Ovario|Clovis Oncology Inc. July 29 2020 --
NCT04209595 Active not recruiting Small Cell Lung Cancer|Extra-Pulmonary Small Cell Carcinomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 8 2020 Phase 1|Phase 2
NCT04179396 Completed Metastatic Castration Resistant Prostate Cancer pharmaand GmbH December 5 2019 Phase 1
NCT03824704 Terminated Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|High Grade Serous Carcinoma|Endometrioid Adenocarcinoma pharmaand GmbH|Bristol-Myers Squibb|Foundation Medicine August 23 2019 Phase 2
NCT03840200 Completed Breast Cancer|Prostate Cancer|Ovarian Cancer Hoffmann-La Roche June 12 2019 Phase 1

Chemical lnformation & Solubility

Molecular Weight 421.36 Formula

C19H18FN3O.H3PO4
CAS No. 459868-92-9 SDF Download Rucaparib phosphate SDF
Smiles CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2.OP(=O)(O)O
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 85 mg/mL ( (201.72 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 7 mg/mL

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Rucaparib phosphate | Rucaparib phosphate supplier | purchase Rucaparib phosphate | Rucaparib phosphate cost | Rucaparib phosphate manufacturer | order Rucaparib phosphate | Rucaparib phosphate distributor